Haben Sie sich noch nicht registriert? Hier kostenlos Ihr Konto eröffnen.
Passwort vergessen? Wir werden Ihnen einen Zurücksetzen Link senden
7 September 2021
Dr. John Stagg, a world-leader in the adenosine pathway, joins Scientific Advisory Board of Tarus Therapeutics, Inc.
27 Mai 2021
Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
28 April 2021
Tarus Therapeutics seeks to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
6 April 2021
Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients
10 März 2021
Tarus Therapeutics seeks to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients
2 Dezember 2020
Tarus Therapeutics Strengthens its Board of Directors with Appointment of Paolo Pucci
24 November 2020
Tarus Therapeutics Expands R&D Team with Appointment of Brian Schwartz, M.D. as Interim Chief Medical Officer and Head of the Scientific Advisory Board
20 Mai 2020
Tarus Therapeutics Strengthens Board of Directors with the Appointment of Preeminent Life Sciences Industry Leaders
23 Dezember 2019
Tarus Therapeutics, Inc., acquires license to Adenosine Receptor Antagonist Platform from Impetis Biosciences, Ltd.